Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Nyheter og Analyser
Nyheter & pressemeldinger
Analyser
3 nov. 21:05
∙
Pressemelding
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
6 okt. 08:00
∙
Pressemelding
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
5 okt. 15:00
∙
Pressemelding
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
29 sep. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
23 sep. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
12 sep. 15:45
∙
Pressemelding
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
8 sep. 20:00
∙
Pressemelding
EQS-News: Abivax Presents First Half 2025 Financial Results
28 juli 20:15
∙
Pressemelding
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
25 juli 06:00
∙
Pressemelding
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
24 juli 12:40
∙
Pressemelding
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
24 juli 12:40
∙
Pressemelding
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
24 juli 05:30
∙
Pressemelding
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
23 juli 20:15
∙
Pressemelding
EQS-News: Abivax Announces Launch of Public Offering
22 juli 20:05
∙
Pressemelding
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
11 juni 20:00
∙
Pressemelding
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11 juni 20:00
∙
Pressemelding
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
2 juni 20:00
∙
Pressemelding
EQS-News: Abivax Presents First Quarter 2025 Financial Results
29 apr. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
22 apr. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
22 apr. 20:00
∙
Pressemelding
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Relaterte produkter
Bull & Bear
2025 Q2-rapport
Kun PDF
92 dager siden
Nyheter og Analyser
Nyheter & pressemeldinger
Analyser
3 nov. 21:05
∙
Pressemelding
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
6 okt. 08:00
∙
Pressemelding
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
5 okt. 15:00
∙
Pressemelding
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
29 sep. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
23 sep. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
12 sep. 15:45
∙
Pressemelding
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
8 sep. 20:00
∙
Pressemelding
EQS-News: Abivax Presents First Half 2025 Financial Results
28 juli 20:15
∙
Pressemelding
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
25 juli 06:00
∙
Pressemelding
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
24 juli 12:40
∙
Pressemelding
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
24 juli 12:40
∙
Pressemelding
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
24 juli 05:30
∙
Pressemelding
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
23 juli 20:15
∙
Pressemelding
EQS-News: Abivax Announces Launch of Public Offering
22 juli 20:05
∙
Pressemelding
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
11 juni 20:00
∙
Pressemelding
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11 juni 20:00
∙
Pressemelding
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
2 juni 20:00
∙
Pressemelding
EQS-News: Abivax Presents First Quarter 2025 Financial Results
29 apr. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
22 apr. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
22 apr. 20:00
∙
Pressemelding
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
United States of AmericaNasdaq
Antall
Kjøp
60
120,29
Selg
Antall
120,76
70
Siste handler
Tid
Pris
Antall
Kjøpere
Selger
-
-
-
-
-
Høy
122,64
VWAP
120,1
Lav
115,76
OmsetningAntall
76,7 1 006 532
VWAP
120,1
Høy
122,64
Lav
115,76
OmsetningAntall
76,7 1 006 532
Risikoinformasjon om aksjehandel
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
6 okt. 08:00
∙
Pressemelding
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
5 okt. 15:00
∙
Pressemelding
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
29 sep. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
23 sep. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
12 sep. 15:45
∙
Pressemelding
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
8 sep. 20:00
∙
Pressemelding
EQS-News: Abivax Presents First Half 2025 Financial Results
28 juli 20:15
∙
Pressemelding
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
25 juli 06:00
∙
Pressemelding
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
24 juli 12:40
∙
Pressemelding
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
24 juli 12:40
∙
Pressemelding
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
24 juli 05:30
∙
Pressemelding
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
23 juli 20:15
∙
Pressemelding
EQS-News: Abivax Announces Launch of Public Offering
22 juli 20:05
∙
Pressemelding
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
11 juni 20:00
∙
Pressemelding
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11 juni 20:00
∙
Pressemelding
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
2 juni 20:00
∙
Pressemelding
EQS-News: Abivax Presents First Quarter 2025 Financial Results
29 apr. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
22 apr. 20:05
∙
Pressemelding
EQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
22 apr. 20:00
∙
Pressemelding
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
Vis alle
Kommende
2025 Q3-rapport
15. des.
6 dager
Historisk
2025 Q2-rapport
8. sep.
2025 Q1-rapport
2. juni
2024 Q4-rapport
24. mars
2024 H2-rapport
24. mars
2024 Q3-rapport
7. nov. 2024
Data hentes fra Quartr, FactSet
Relaterte produkter
Bull & Bear
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
United States of AmericaNasdaq
Antall
Kjøp
60
120,29
Selg
Antall
120,76
70
Siste handler
Tid
Pris
Antall
Kjøpere
Selger
-
-
-
-
-
Høy
122,64
VWAP
120,1
Lav
115,76
OmsetningAntall
76,7 1 006 532
VWAP
120,1
Høy
122,64
Lav
115,76
OmsetningAntall
76,7 1 006 532
Risikoinformasjon om aksjehandel
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.